Business Description
iBio Inc. is a San Diego-based biotechnology company in the preclinical stage, using artificial intelligence to discover and develop antibody treatments targeting cancer, obesity, and related metabolic conditions. The company has built a suite of proprietary platforms that improve how antibodies are designed, activated, and directed toward specific disease targets, enabling more precise therapies with fewer side effects. Its current pipeline includes several cancer-focused antibody candidates aimed at boosting the immune system's ability to destroy tumors while protecting healthy tissue. Through a partnership with AstralBio, iBio is also working to expand its AI-driven approach into obesity and cardiometabolic disease.
